Briefing
Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma (MIDAS)
Phase 3 randomized MRD-guided consolidation after Isa-KRd induction. Among 485 patients MRD-negative at 10^-5 after induction, premaintenance MRD negativity at 10^-6 was 86% with ASCT + 2 cycles Isa-KRd vs 84% with 6 cycles Isa-KRd without ASCT (adjusted RR 1.02, 95% CI 0.95-1.10, P=0.64). Among 233 patients MRD-positive at 10^-5, premaintenance 10^-6 negativity was 32% with tandem ASCT vs 40% with single ASCT + Isa-KRd (adjusted RR 0.82, 95% CI 0.58-1.15, P=0.31). Median follow-up about 16-17 months. Neither intensification strategy significantly improved the 10^-6 MRD endpoint. Level 1 (randomized MRD-guided trial).
- Design: paper
- n: 485 MRD-negative at 10^-5 after induction; 233 MRD-positive at 10^-5
- Assay: NGS MRD, 10^-5 to assign consolidation; primary endpoint 10^-6 MRD negativity before maintenance